Fluoride uptake and retention at various stages of rat molar enamel development

Suckling rat pups were given intraperitoneal fluoride injections at selected ages so that we could study fluoride uptake in the enamel of the maxillary first molar at various stages of enamel development. Plasma fluoride levels in six-day-old and 11-day-old pups were monitored following the intraperitoneal injection of fluoride. The findings indicate that: (1) fluoride was more easily taken up and retained during the early stages of enamel formation, but fluoride uptake can occur during all stages of enamel formation; (2) when injections were started early in enamel formation, more fluoride was contained in the enamel of the maxillary first molar at 13 days of age; and (3) the same dose of fluoride per gram body weight resulted in greater exposure to elevated plasma fluoride levels in six-day-old pups than in 11-day-old pups.     

Reversed vein graft stenosis: early diagnosis and management.

Conscientious surveillance of intrainguinal bypass grafts is mandatory to detect vein graft stenoses, which, if uncorrected, can lead to graft occlusion. It is now widely accepted that noninvasive vascular laboratory studies are the best way to detect these lesions. However, controversy still exists over treatment, specifically whether balloon angioplasty is an acceptable substitute for surgery (patch angioplasty or short jump grafts) in the treatment of these lesions. We have always favored balloon angioplasty as primary treatment and have summarized our experience with treating 72 stenotic reversed femoropopliteal and femorotibial vein grafts, which represent 12% of 521 bypass grafts performed at our institution. Prosthetic and in situ grafts are specifically excluded from this report, as well as occluded grafts, found to have stenotic lesions after lytic therapy. The most common stenotic lesion occurred within 4 cm of the proximal anastomosis (29/72 = 40%). The other sites were near the distal anastomosis (7/72 = 10%), and in the middle of the graft (15/72 = 12%). Eighty-one percent (58/72) of the lesions were treated initially by balloon angioplasty with a 31% recurrence. Twenty-nine percent of the 14 grafts treated surgically by vein patch angioplasty or short jump grafts experienced recurrence. Overall 61% (44/72) of the stenotic grafts were treated by balloon angioplasty alone. The 5-year life-table assisted primary patency after correction of the stenotic lesion was 61%. The patency of the grafts from the time of initial bypass surgery, however, was 80%. Location of the stenosis within the graft was a major determinant of patency. Lesions in the proximal graft, proximal anastomosis, and distal graft taken as a group had significantly better patency than the midgraft and distal anastomotic lesions (5-year patency, 65% vs 48%, p less than 0.001 log rank test). We continue to recommend balloon angioplasty as primary therapy for vein graft stenosis except for those occurring in the midgraft and distal anastomosis. Fortunately, this group accounts for only 36% of lesions seen with reversed veins. Recurrent stenosis after balloon angioplasty should be repaired surgically.     

Time course of transient expression of GDNF protein in rat granule cells of the bilateral dentate gyri after unilateral intrahippocampal kainic acid injection

We examined the time course of expression of glial cell line-derived neurotrophic factor (GDNF) protein in the granule cells of the dentate gyrus following unilateral intrahippocampal injection of kainic acid (KA). Recurrent behavioral seizures were observed approximately 1 h after KA injection, which lasted for 4-6 h. GDNF immunoreactivity began to increase bilaterally in the granule cells within 3 h after KA injection, continued to increase until post-injection day (PID) 4, and returned to the control level by PID 7. The results suggest that the increase of GDNF protein in the granule cells may be ascribable to seizures induced by the KA injection. The increase of GDNF protein might promote survival of the granule cells after the intrahippocampal KA injection.     

Optimal Duration and Temperature of Prewarming

Background: Core hypothermia developing immediately after induction of anesthesia results largely from an internal core-to-peripheral redistribution of body heat. Although difficult to treat, redistribution can be prevented by prewarming. The benefits of prewarming may be limited by sweating, thermal discomfort, and efficacy of the warming device. Accordingly, the optimal heater temperature and minimum warming duration likely to substantially reduce redistribution hypothermia were evaluated.

Methods: Sweating, thermal comfort, and extremity heat content were evaluated in seven volunteers. They participated on two study days, each consisting of a 2-h control period followed by 2 h of forced-air warming with the heater set on "medium" ([nearly equal] 40 degrees Celsius) or "high" ([nearly equal] 43 degrees Celsius). Arm and leg tissue heat contents were determined from 19 intramuscular needle thermocouples, ten skin temperatures, and "deep" foot temperature.

Results: Half the volunteers started sweating during the second hour of warming. None of the volunteers felt uncomfortably warm during the first hour of heating, but many subsequently did. With the heater set on "high," arm and leg heat content increased 69 kcal during the first 30 min of warming and 136 kcal during the first hour of warming, representing 38% and 75%, respectively, of the values observed after 2 h of warming. The increase was only slightly less when the heater was set to "medium."     

Safety of tiagabine: summary of 53 trials

We reviewed the clinical safety of tiagabine HCl (TGB), a selective CNS GABA uptake inhibitor, in nearly 3100 patients from 53 separate clinical trials. TGB was found to have no clinically important effect upon hepatic metabolic processes, serum concentrations of concomitant antiepileptic drugs (AEDs), laboratory values, or important interactions with any common non-AEDs. Adverse effects were usually mild and involved the nervous system. TGB is safe and well-tolerated as add-on therapy for the treatment of partial seizures.     

Nocturnal Blood Pressure Non-Dipping,Posttraumatic Stress Disorder,and Sleep Quality in Women

Women with posttraumatic stress disorder (PTSD) have poor sleep quality and increased risk of cardiovascular disease (CVD). Non-dipping of nocturnal blood pressure may be an explanatory factor for the relationship between sleep and CVD found in previous research. The current study was designed to determine if non-dipping nocturnal blood pressure was associated with trauma exposure, PTSD diagnosis, PTSD symptoms, and sleep quality in a sample of women. Participants completed 24 hours of ABPM and self-report questionnaires. Non-dipping was defined as less than 10% reduction in blood pressure during sleep. The frequency of non-dippers did not differ by diagnostic status (d = .15). However, non-dippers endorsed more traumatic event categories (d = .53), more PTSD hyperarousal symptoms (d = .53), poorer overall sleep quality (d = .59), more frequent use of sleep medication (d = .62), greater sleep-related daytime dysfunction (d = .58), and longer sleep onset latencies (d = .55) than dippers. Increased attention to nocturnal blood pressure variation may be needed to improve blood pressure control in trauma-exposed women.